Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional rituximab for orbital lymphoma
2007-007799-40Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in Orbital Lymphoma (OL) and mature B-cell lymphoma, sponsored by Policlinico Gemelli. Primary endpoint: Safety and efficacy of intralesional rituximab. Started Dec 2007; status: completed.
02
Drugs
rituximab
03
Conditions
Orbital Lymphoma (OL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2007-007799-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007799-40.